PDCD1 and neoplasm: Combination treatment resulted in 51% TGI, whereas neither single agent demonstrated any meaningful tumor growth inhibition (Fig. 5C), suggesting a synergistic antitumor effect in this model with niraparib and PD-1 resistance.